NanoViricides wins DRC approval for Phase II trial of NV-387 oral gummies for Ebola treatment
NNVC•DR Congo approval for Phase II trial
- NanoViricides won ACOREP clearance in DR Congo to launch a Phase II trial of NV-387 oral gummies for Bundibugyo ebolavirus.
- Om Sai Clinical Research was hired as CRO; drug supply for trial start is already in-country.
